Form 4: Entero Therapeutics CEO Receives Stock Grant
Insider Transaction (Form 4)
Jason David Sawyer, Chief Executive Officer and a Director of Entero Therapeutics, Inc., received 250,000 shares of common stock on September 30, 2026.
Summary
- Grant/award: acquired 250,000 Common Stock on September 30, 2026; holds 790,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Jason David Sawyer — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-30 | Grant/award | Common Stock | 250,000 | — | — | 790,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-30 | Grant/award (250,000 shares) |
Keywords
insider transaction, Form 4, GRDX, GridAI Technologies Corp., neutral, Jason David Sawyer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.